Semaglutide prescription FAQ — everything patients ask before starting.

You need a prescription from a licensed healthcare provider. Three main pathways: (1) your primary care physician or endocrinologist, (2) a weight management clinic or med spa, or (3) a licensed telehealth provider specializing in GLP-1 prescribing. The telehealth route is fastest — most patients complete evaluation and receive a prescription within 24–48 hours.

Yes. Licensed telehealth providers can evaluate and prescribe semaglutide via virtual consultation in all 50 states. The prescriber conducts medical history review, assesses eligibility, and if appropriate, sends the prescription directly to a licensed compounding pharmacy. Medication ships to your door.

No. Telehealth prescribing is fully legal in all US states. Some providers require synchronous video consultation; others use asynchronous evaluation. Both are valid under state telehealth laws. Some providers may require baseline lab work at a local facility.

Telehealth evaluations can typically be completed within 24–48 hours. If a prescriber determines compounded semaglutide is clinically appropriate, the prescription is sent to a licensed compounding pharmacy. Timelines vary by provider and pharmacy.

Semaglutide is available at weight management clinics and med spas in most metro areas. However, telehealth eliminates the need for a local clinic — evaluation and prescribing happen remotely, and medication ships directly to you regardless of location.

Compounded semaglutide from licensed 503A pharmacies operating under USP 797 sterile standards is considered safe. The active ingredient is identical to brand-name. Verify your pharmacy is properly licensed, uses FDA-registered suppliers, and provides certificates of analysis. Quality varies — use a reputable pharmacy recommended by your prescriber.

The molecule is identical. Differences: delivery (vial + syringe vs pre-filled pen), formulation excipients, cost (70–85% less), and regulatory status (503A compounding authority vs FDA-approved NDA). See the full compounded vs brand comparison.

Clinical trials showed 15–17% total body weight loss at 2.4 mg over 68 weeks. For a 200 lb person, that's approximately 30–34 lbs. Results vary based on starting weight, dietary changes, activity level, and individual metabolic response. See the full weight loss timeline.

Currently considered long-term medication for weight management. The STEP 4 trial showed patients who discontinued after reaching target weight regained approximately two-thirds of lost weight within 12 months — consistent with obesity being a chronic condition requiring ongoing management.

Semaglutide is a GLP-1 agonist. Tirzepatide (brand-name tirzepatide) is a dual GIP/GLP-1 agonist. Clinical trials suggest tirzepatide may produce slightly greater weight loss (up to 22% vs 15–17%), though head-to-head data is limited. Both are available through compounding pharmacies during their respective shortages.

The FDA declared the semaglutide shortage resolved in February 2025 and removed it from the Drug Shortage Database. The shortage-based compounding exemption has ended. However, 503A pharmacies may still compound semaglutide under traditional compounding authority when a prescriber documents a patient-specific clinical need. Federal court challenges to the FDA's determination remain ongoing as of April 2026.

Semaglutide is the active ingredient in brand-name formulations for both diabetes and weight management. They are the same molecule — a 31-amino-acid GLP-1 receptor agonist. Compounded semaglutide also contains the identical active ingredient.